

Search

EN

Back

Ascletis Targets Obesity Market with Oral Drug, Aims for 2026 FDA Filing

Back

Stock NewsThemesAscletis Targets Obesity Market with Oral Drug, Aims for 2026 FDA Filing

Ascletis Targets Obesity Market with Oral Drug, Aims for 2026 FDA Filing

Edgen Stock·Feb 11 2026, 00:18

Share to

Share to

Copy link

ASCLETIS-B+1.10%

source:

[1] Ascletis Pharma: Selected oral amylin receptor agonist peptide ASC36 for clinical development

Recommend

Apple Stock Climbs as Investors Shun Big Tech's $650B AI SpendingFeb 18 2026, 00:32 Similarweb Swings to Profit, Beating Q4 EstimatesFeb 17 2026, 23:58 Hormel Sells Turkey Business, Reaffirms 2026 GuidanceFeb 17 2026, 23:57

Hot News

Tesla Produces First Cybercab, Advancing Robotaxi NetworkFeb 18 2026, 01:06

Hecla Mining Q4 EPS Soars 375%, Crushing EstimatesFeb 18 2026, 00:59

Caterpillar Acquires RPMGlobal to Expand Mining Software UnitFeb 18 2026, 00:58

Software Firms Release Early Data to Counter AI Debt RoutFeb 18 2026, 00:38

Features

AI Copilot for Stock & Crypto

Price Prediction

Fundraise Tracker

Crypto Comparison

Resources

Market

Terms of Use Privacy Policy Sitemap

© 2026 Finture Development Limited. All rights reserved